Kimura T, Enosawa S, Kamada N, Kobayashi E, Toyama N, Doy M, Matsuzaki Y, Tanaka N, Osuga T
Department of Experimental Surgery, National Children's Medical Research Centre, Tokyo, Japan.
Transpl Immunol. 1995 Dec;3(4):299-304. doi: 10.1016/0966-3274(95)80015-8.
We examined the changes in the levels of soluble major histocompatibility antigen complex (MHC) class I antigens in the serum under a lethal or nonlethal state of graft-versus-host-disease (GVHD) induced by injecting various doses of PVG rat splenic lymphocytes into (DA x PVG)F1 rats. All rats receiving 4 x 10(8) lymphocytes (lethal dose) died on day 20-36 showing typical features of GVHD, while the injection of 4 x 10(7) cells (nonlethal dose) induced no sign of GVHD. When rats were inoculated with a nonlethal dose of lymphocytes prior to the injection of a lethal dose, all rats survived with or without showing transient GVHD. Preceding the onset of GVHD the levels of soluble class I antigens increased significantly to 1094 +/- 487 ng/ml (mean +/- SD, n = 4) from 3 days after the injection of a lethal dose to the time of death, whilst the levels in the nonlethal dose group remained unchanged. Rats with transient GVHD in the preinoculated group showed the increase of soluble class I antigens to the same extent as rats with lethal GVHD, suggesting that GVHD was systemically ongoing. The levels of soluble class I antigens also correlated with the severity of GVHD as judged by daily observation and histological studies. Rats receiving a lethal dose showed destructive alteration of spleen structure and cellular infiltration in the portal area of the liver before the animals started to show signs of GVHD, whereas rats in the nonlethal dose group exhibited no marked change. These data suggest the possibility of serum soluble class I antigens being not only a diagnostic but also a prognostic marker for GVHD.
我们研究了通过向(DA×PVG)F1大鼠注射不同剂量的PVG大鼠脾淋巴细胞诱导的移植物抗宿主病(GVHD)致死或非致死状态下血清中可溶性主要组织相容性抗原复合物(MHC)I类抗原水平的变化。所有接受4×10⁸淋巴细胞(致死剂量)的大鼠在第20 - 36天死亡,表现出GVHD的典型特征,而注射4×10⁷个细胞(非致死剂量)未诱导出GVHD的迹象。当大鼠在注射致死剂量淋巴细胞之前接种非致死剂量的淋巴细胞时,所有大鼠均存活,无论是否表现出短暂的GVHD。在GVHD发作之前,可溶性I类抗原水平从注射致死剂量后3天到死亡时显著增加至1094±487 ng/ml(平均值±标准差,n = 4),而非致死剂量组的水平保持不变。预接种组中出现短暂GVHD的大鼠可溶性I类抗原增加的程度与致死性GVHD大鼠相同,表明GVHD正在全身发生。可溶性I类抗原水平也与通过每日观察和组织学研究判断的GVHD严重程度相关。接受致死剂量的大鼠在开始出现GVHD迹象之前,脾脏结构出现破坏性改变,肝脏门区有细胞浸润,而非致死剂量组的大鼠则无明显变化。这些数据表明血清可溶性I类抗原不仅有可能作为GVHD的诊断标志物,还可能作为预后标志物。